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Available online 9 March 2016Background: Although magnesium (Mg) has recognized cardioprotective properties and hypomagnesemia
is common in patients with acute myocardial infarction (AMI), data regarding the role of Mg as prognostic
factor for adverse events are scarce, as well as there are conﬂicting results on the use of Mg as adjuvant therapy
in AMI.
Aim: To evaluate the role of Mg as predictor for hard events (HE, all cause death, and nonfatal myocardial
infarction) in AMI patients.
Design and patients:We studied 406 AMI patients (306males, age: 67±12 years,mean± SD). Patient data were
collected from the Institute electronic databank which saves demographic, clinical, instrumental, therapeutical
and follow-up data of all patients admitted to our Coronary Unit.
Results: During a mean follow-up period of 21 ± 18 months, the combined endpoint accounted for 63 HE, 44
(11%) deaths (35 cardiac deaths), 19 (5%) nonfatal MI.
The multiple regression model identiﬁed glycemia as the only independent determinant of Mg in AMI pts.
(T value = −2.8, standard coefﬁcient = −0.15, p b 0.01). The Kaplan–Meier survival estimates failed to
show a signiﬁcantly worst outcome in patients presenting low Mg (b0.783 mmol/L, 25th percentile).
Aging (N67 years—50th percentile), and ejection fraction (b40%) remained as prognostic factors for HE in the
adjusted Cox multivariate proportional hazard model (HR = 2.8, 95% CI = 1.6–5, p b 0.001; HR = 3.2, 95%
CI = 1.9–5.3 p b 0.001, respectively).
Conclusion: The present ﬁndings do not support a signiﬁcant role of low Mg as predictor for HE in AMI.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Magnesium (Mg) is an essential element and an activator of a
number of enzymes, which retains β-adrenoreceptor blocking action,
antiplatelet effects, and antiarrhythmic, antivasospastic and other im-
portant cardiovascular (CV) protective effects, supporting the rationale
for its use in acute myocardial infarction (AMI) [12]. From ﬁrst promis-
ing results in experimental studies, several other clinical trials evaluated
the efﬁcacy of Mg adjuvant therapy in the secondary prevention of CV
disease [18]. Nonetheless, whether some previous, relatively small
randomized clinical trials demonstrated improved survival, other trials
could not demonstrate any beneﬁt [18]. In particular, two publishedrio CNR-Regione Toscana and
isa, Italy.
. This is an open access article underlarge-scale randomized studies – the Fourth International Study of
Infarct Survival and Magnesium in Coronaries – did not evidence any
advantage in terms of survival of intravenous Mg over placebo [8,15].
Also the relationship between dietary Mg and CV risk has not been
clearly established [4,9]. In a meta-analysis of 5 studies, dietary Mg
intake was not associated with total CV disease risk (RR comparing
high versus low Mg intake, 0.86; 95% CI, 0.67 to 1.10) [21]. Other
population-based studies, that have evaluated the relationship between
Mg and CV events, also reported conﬂicting result [10,17,21].
Mg represents a low-tech, low-cost and easily accessible biomarker
to be used in the clinical setting. However, a direct relationship between
blood and/or dietary Mg and CV disease risk has not been clearly
established. Moreover, despite the numerous reports on its potential
CV beneﬁts and the use as an adjuvant therapy in AMI, its effective
prognostic value in AMI is still not cleared.
The aim of the present study was to evaluate the predictive value of
Mg for hard events (HE: mortality and non fatal myocardial infarction,
MI) in AMI patients.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Levels ofMg in patientswith andwithout events.Median, interquartile, outliers and
extremes of Mg are given.
Fig. 2. Kaplan–Meier survival curves for Hard Events according to Mg 25th percentile
(corresponding to 0.783 mmol/L).
Table 1
Clinical characteristics according to magnesium 25th percentile.
Mg
Characteristic b0.783
mmol/L
≥0.783
mmol/L
p
Number of pts 101 305
Age (years) 67 ± 11 66 ± 13 ns
Males 70 (69) 236 (77) ns
Body mass index (kg/m2) 26 ± 4 27 ± 4 ≤0.05
Mean arterial pressure (mm Hg) 92 ± 15 94 ± 15 ns
Glycemia (mg/dL) 137 ± 65 119 ± 43 ≤0.001
Total cholesterol (mg/dL) 187 ± 46 193 ± 41 ns
High density lipoproteins (mg/dL) 40 ± 12 41 ± 11 ns
Triglycerides (mg/dL) 128 ± 111 128 ± 78 ns
Low density lipoproteins (mg/dL) 121 ± 39 127 ± 35 ns
Smoking habit 60 (56) 143 (48) ns
Family history of coronary artery disease 42 (42) 138 (45) ns
Ejection fraction (%) 46 ± 10 46 ± 11 ns
Multi-vessel disease 55 (51) 170 (57) ns
Data presented are mean ± DS or number (%) of patients.
Diabetes mellitus = fasting plasma glucose N 126 mg/dL or use of antidiabetic treatment.
Hypertension = systolic blood pressure N 140 mm Hg and/or diastolic pressure N 90 mm
Hg or by the use of antihypertensive medication.
Dyslipidemia = total cholesterol concentration was ≥ 200 mg/dL, or triglyceride concen-
tration ≥ 150 mg/dL, or current use of lipid-lowering drugs.
ns = not signiﬁcant.
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2.1. Subjects
Subjects selected to participate in the study were 406 patients (306
males, age: 67 ± 12 years, mean ± SD), consecutively admitted (period
2002–2008) to the Coronary Care Unit of the CNR Institute of Clinical
Physiology in Pisawithin 48 h after onset of symptoms of AMI symptoms.
In this retrospective study, information were extracted from the
IMAGE database, which contains detailed information on demographic,
clinical, laboratory, instrumental, therapeutical and follow-up data of all
consecutive patients admitted to the Coronary Unit [3,22].
Left ventricular function was estimated by echocardiography at
discharge. Data on smoking habit (never smokers, ex smokers – who
had quit smoking for at least 6 months – and current smokers), family
history of ischemic heart disease, arterial hypertension (systolic blood
pressure SBP N 140 mm Hg and/or diastolic pressure DBP N 90 mm Hg
or antihypertensivemedication), diabetes (twice fasting plasma glucose
N126 mg/dL or antidiabetic treatment), obesity (body mass index, BMI;
N30 kg/m2), and dyslipidemia (total cholesterol ≥200 mg/dL, or triglyc-
erides ≥150 mg/dL, or lipid-lowering treatment) were coded in a
dichotomized fashion. Medical therapy included ACE inhibitors, beta-
blockers, lipid-lowering, anti-diabetic agents, diuretics, aspirin, nitrates
and calcium-channel antagonists.
2.2. Follow-up
Following discharge, the follow-up program included an annual
telephone interview with patients or family members and validation
of HE [3]. The endpoints included cardiac death, all-cause death, and
new myocardial infarction. Patients were censored after the ﬁrst
major event during follow-up. The cause of death was derived from
medical records or death certiﬁcates provided by local health authori-
ties. The diagnosis of AMIwas based on the documentation of persistent
electrocardiographic ST segment changes or new Qwave development,
associated with increase of cardiac speciﬁc biomarkers.
2.3. Statistical analysis
Data were expressed as the mean ± SD. Statistical analysis
performed included Student's t test, χ2 test, and linear regression.Owing to skewness, log transformations of glycemia and glycated
hemoglobin, were used for statistical analyses. Log-transformed values
were then back-transformed for data presentation.
The multiple regression analysis was performed to determine inde-
pendent correlates of Mg levels. Cumulative event rates were estimated
by Kaplan–Meier survival curves and probability values determined
with the log-rank test. For survival analysis, only one event was consid-
ered in each patient. Statistical analysis also included Cox proportional
hazard models to determine independent predictors of HE.
Variables were selected if they had a p value 0.05 on univariate
analyses and added for multivariate adjustment. A p value 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Characteristics of patients and Mg determinants
In the study, 406 patients with AMI were enrolled. The average age
of the whole population was 67 ± 12 years and 75% (n = 306) of
them were males.
Characteristics of Mg distribution were: mean (SD), 0.842 (0.1)
mmol/L; range 0.52—1.2 mmol/L; skewness—0.1; and kurtosis 0.7.
The prevalence of baseline risk factors according to Mg 25th quartile
(corresponding to 0.783 mmol/L) is reported in Table 1.
Glycated hemoglobin, available in a subset of 143 patients, inversely
correlated with Mg values (r =−0.18, p b 0.05). After the adjustment
at the multivariate regression analysis, glycemia (T value = −2.8,
Table 2
Cox predictive model for Hard Events.
Predictors Univariate analysis Multivariate analysis
Hazard ratio 95% conﬁdence intervals p Hazard ratio 95% conﬁdence intervals p
Age (N67 years—50th percentile) 3.2 1.8–5.6 b0.001 2.8 1.6–5 b0.001
Males 1.05 0.6–1.9 ns
Hypertension 1.2 0.7–2.0 ns
Type 2 diabetes 1.02 0.6–1.8 ns
Dyslipidemia 1.1 0.6–1.9 ns
Smoking habit 0.8 0.5–1.3 ns
Family history of coronary artery disease 0.8 0.5–1.3 ns
Obesity (BMI N 30 kg/m2) 0.8 0.4–1.5 ns
Mg (b0.783 mmol/L) 0.99 0.6–1.7 ns
Ejection fraction b40% 3.5 2.1–5.8 b0.001 3.2 1.9–5.3 b0.001
Multi-vessel disease 1.8 1.1–3.0 b0.5 1.2 1–2.1 ns
Diabetes mellitus = fasting plasma glucose N 126 mg/dL or use of antidiabetic treatment.
Hypertension = systolic blood pressure N 140 mm Hg and/or diastolic pressure N 90 mm Hg or by the use of antihypertensive medication.
Dyslipidemia = total cholesterol concentration was ≥ 200 mg/dL, or triglyceride concentration ≥ 150 mg/dL, or current use of lipid-lowering drugs.
ns = not signiﬁcant.
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dent determinant for lower Mg level.
3.2. Outcome
During a mean follow-up period of 21 ± 18 months, the combined
endpoint accounted for 63 events; therewere 44 (11%) deaths (35 cardi-
ac deaths), and 19 (5%) patients had nonfatal myocardial infarctions. No
differenceswere observed regarding theMg level between patients with
and without events (Fig. 1). The Kaplan-Meier survival estimate for HE
failed to show a signiﬁcantly worst outcome in patients presenting low
Mg (b0.783 mmol/L, 25th percentile) (Fig. 2). Aging (N67 yrs-50th per-
centile), and ejection fraction (b40%) remained as signiﬁcant prognostic
factors for HE in the adjusted Cox multivariate proportional hazard
model (HR = 2.8, 95% CI = 1.6-5, p b 0.001; HR = 3.2, 95% CI = 1.9-
5.3 p b 0.001, respectively) (Table 2).
4. Discussion
We did not ﬁnd a signiﬁcant association between Mg levels and
subsequent HE in AMI patients.
Mg, which is the physiological calcium antagonist, protects from
oxidative damage, improves endothelial function and inhibits platelet
aggregation and adhesion [18]. Mg supplementation improves myocar-
dial metabolism, inhibits calcium accumulation and myocardial cell
death, improves vascular tone, peripheral vascular resistance, afterload
and cardiac output, reduces cardiac arrhythmias and improves lipid
metabolism [18]. Conversely, hypomagnesemia is associated with an
increased incidence of CV risk factors, and arrhythmias particularly in
association with congestive heart failure, and more rapid progression
of kidney disease, among others adverse health consequences [18].
Levels ofMg have been documented reduced in AMI [1,16,20]. In this
context, dated results suggested that lower Mg in AMI patients was
essentially due to increased demand during AMI, rather than dietary
intake differences [20]. Clinical studies investigating the role ofMg adju-
vant therapy on mortality after AMI have produced conﬂicting results.
The Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)
(n = 2316 patients), evidenced a reduction in the 28-day mortality
rate in patients receiving Mg therapy compared with control subjects
[23]. Long-term follow-up of these patients showed a 16% reduction in
the all-cause mortality rate in the Mg-treated group [23]. Subsequent
ISIS-4 (n = 58,050 patients) and MAGIC studies (n = 6213 patients)
did not report any advantage conferred by adjuvant Mg therapy to
standard on 5-week mortality in myocardial infarction patients [8,15].
In the ISIS-4 trial the incidence of heart failure was even signiﬁcantly
higher in the Mg-group [15]. Nonetheless, one main critical to ISIS-4 is
in the timing of Mg administration. Indeed, more recent research hasfurther conﬁrmed the time-dependent effect of Mg when given for
both myocardial protection in experimental ischemia-reperfusion inju-
ry and for antithrombotic effects [15].
Majority of population studies that have evidenced the relationship
between Mg status and CV outcomes were based on dietary intake,
which may be inﬂuenced by residual confounding or recall bias [18].
The few studies focused on the relationship betweenMg and CV disease
events have produced controversial results. An analysis from the ARIC
cohort (13,922 healthy subjects without CAD on admission) showed a
signiﬁcant association between Mg and coronary heart disease in
women but not men [14]. However, we did not observe any difference
in terms of signiﬁcance on HE between men and women in our AMI
population (data not shown). In the National Health and Nutrition
Examination Survey Epidemiologic Follow-up Study (NHANES) Mg was
inversely associated with CV and all-cause mortality [5,6]. More recent
data in a German population-based sample evidenced lowMg concentra-
tion as independent predictor of all-cause and CVmortality also after ad-
justment for CV risk factors, including diabetes and hypertension [17]. Mg
was also found to be associated with CV and all-cause mortality in
middle-agedmen (n=4035) in the Paris Prospective Study [13]. Notably,
none of our patients showed severe hypomagnesemia (≤0.494 mmol/L),
as in other cohorts of patients [5,13], thus it is not possible for us to
drawconclusions about the risk associatedwith a very lowMg.Moreover,
a recent analysis of the Framingham Heart Offspring Cohort, did not evi-
dence any association between Mg, incident arterial hypertension, and
all cause mortality in the adjusted statistical models [10]. Recent data
also suggest that low Mg is predictor of major adverse cardiac events in
patients with AMI, but not in those with unstable angina [2].
Mg is a common biomarker measured in biochemical laboratory,
although it is predominantly an intracellular cation [12]. Thus, it has
been supposed that the measurement of circulating Mg might not
reﬂect total body Mg stores. Accordingly, serial measurements or a
measure of intracellular Mg, such as that contained in lymphocytes,
erythrocytes or myocytes, may provide a more precise assessment of
the trueMg status [19,22]. Conversely, other data suggest thatMg circu-
lating concentrationmay represent an effective index ofMg status given
that levels well correlate with ionized Mg and intracellular Mg [7,11].
In conclusion, actually the relationship between MG and coronary
artery disease as well as beneﬁt from use of Mg in AMI clinical setting
are not clearly delineated in view of available contrasting literature
data. In this context, our ﬁndings do not support a role for low Mg as
adverse prognostic factor for HE in AMI patients.
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